Financials data is unavailable for this security.
View more
Year on year Intellia Therapeutics Inc had revenues fall -30.40% from 52.12m to 36.28m, though the company grew net income from a loss of 474.19m to a smaller loss of 481.19m.
Gross margin | -- |
---|---|
Net profit margin | -1,212.19% |
Operating margin | -1,247.99% |
Return on assets | -43.22% |
---|---|
Return on equity | -52.23% |
Return on investment | -47.07% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Intellia Therapeutics Inc fell by 295.11m. Cash Flow from Financing totalled 130.32m or 359.26% of revenues. In addition the company used 394.09m for operations while cash used for investing totalled 31.35m.
Cash flow per share | -5.36 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.46 |
---|---|
Tangible book value per share | 9.46 |
More ▼
Balance sheet in USDView more
Current ratio | 6.73 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼